)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Context Therapeutics
Context Therapeutics (CNTX) investor relations material
Context Therapeutics TD Cowen 46th Annual Health Care Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.TD Cowen 46th Annual Health Care Conference summary3 Mar, 2026
Strategic focus and pipeline overview
Focused on developing T-cell engagers, a class of antibodies that bridge immune cells and cancer cells using tumor antigens as targets.
Pipeline includes three externally discovered programs: Claudin 6 (CT76), mesothelin (CT-95), and Nectin-4 (CT-202), all targeting solid tumors.
Claudin 6 targets ovarian, endometrial, and testicular cancers; mesothelin targets pancreatic, ovarian, and mesothelioma; Nectin-4 targets multiple tumors including triple-negative breast, bladder, and lung cancers.
Nectin-4 program entering the clinic in Q2, with ongoing and upcoming quarterly clinical updates.
Emphasis on high-affinity CD3 for potent immune activation and a capital-efficient model focused on clinical advancement.
Clinical development and data milestones
Claudin 6 phase I data to be disclosed in Q2, focusing on ovarian cancer with a robust dataset of 10–12 patients at target dose.
Mesothelin phase I data expected mid-2026, with current focus on pancreatic, ovarian, and mesothelioma indications.
Nectin-4 clinical trial design and tumor targets to be disclosed soon, with first-in-clinic activities planned for Q2.
Quarterly clinical updates anticipated for all programs starting Q2 onward.
Well-financed with $115 million raised in 2025, supporting all key inflection points.
Scientific and competitive positioning
T-cell engagers offer rapid adoption and superior sales growth compared to ADCs, with increasing approvals in solid tumors.
Claudin 6 program shows high selectivity and promising preclinical efficacy, with potential to address ADC-resistant ovarian cancer.
Mesothelin program engineered for low lung toxicity, differentiating from competitors through lower affinity binding and safety profile.
Nectin-4 program uses pH-dependent binding to reduce skin toxicity, with preclinical data showing minimal IL-6 induction and robust efficacy.
Limited competition in Nectin-4 space, with unique CD3-based approach and broad patient eligibility.
How is Claudin 6 liver toxicity managed?
Explain the rationale for low-affinity mesothelin binder.
Nectin-4: What are key expansion indications?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Next Context Therapeutics earnings date
Leerink Global Healthcare Conference 202611 Mar, 2026
Context Therapeutics
Next Context Therapeutics earnings date
Leerink Global Healthcare Conference 202611 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies for solid tumors. The company's primary focus is on T cell-engaging bispecific antibodies, including its lead candidate, CTIM-76. This investigational therapy targets Claudin 6 (CLDN6), a protein expressed in various solid tumors such as ovarian, endometrial, and testicular cancers, while being minimally present in healthy tissues. Another key candidate in their pipeline is CT-95, a bispecific antibody targeting mesothelin, which is also aimed at treating solid tumors. Context Therapeutics is headquartered in Philadelphia, Pennsylvania, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage